Qalsody Economics and ALS Gene Therapy

Qalsody (tofersen), the first FDA-approved gene therapy for ALS targeting SOD1 mutations, highlights both the promise and the economic challenges of rare-disease innovation. Developed over more than a decade by Ionis Pharmaceuticals and commercialized by Biogen, Qalsody is estimated to have cost $4–5 billion to bring to market, driven by complex science and a very small patient population. Despite its breakthrough status, limited eligibility, high annual treatment costs, and payer resistance mean profitability is modest, with revenues unlikely to fully recoup development expenses for many years. Economically, Qalsody serves as a critical case study for future ALS gene therapies, underscoring the need for biomarkers, partnerships, and new pricing models to make innovation sustainable. als.COMMUNITY is a free, one-stop platform for everyone impacted by ALS. We bring together patients, caregivers, family, clinicians, and researchers to share, learn, and connect. Join our community today: www.als.community Follow Us: Instagram: https://www.instagram.com/als.community/ Facebook: https://www.facebook.com/als.community #ALS